A nutrition care support and efficacy of Levocarnitine Chloride(We change it to Levocarnitine from May 15,2015) in patients with NAFLD patients

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000013760

Enrollment

Registered

2014-04-18

Start date

2014-02-05

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

NAFLD

Interventions

The follow-up by the nutrition education 3 months Levocarnitine Chloride at a600mg(We change it to Levocarnitine at a500mg from May 15,2015) thrice daily for 6 months

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patients who had a diagnosis of NAFLD by liver biopsy with using echo guide in this hospital

Exclusion criteria

Exclusion criteria: Pacemaker wearing The metal patients who enter who we have history of bone fracture, and are artificial

Design outcomes

Primary

Measure	Time frame
hematologic biochemical test (AST?ALT?gamma-GTP?TC?LDL?TG?FBS?UA?insulin?IRI?Fe?Ferritin) Body fat measurement using CT physical measurement body component analysis(In Body)	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026